Showing results (211-220 of 589) with videos related to
Sort By:
Pageof 59
Journal of Neuro-Oncology|April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor eraDaniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.Cancer|February 2, 2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanomaRupal S Bhatt, Jaime Merchan, Robert Parker, et al.The Lancet. Oncology|December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label studyBrian I Rini, Sumanta K Pal, Bernard J Escudier, et al.Nature Reviews. Disease Primers|April 3, 2025
Cutaneous melanomaAlpaslan Tasdogan, Ryan J Sullivan, Alexander Katalinic, et al.Journal for Immunotherapy of Cancer|May 17, 2020
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitisMeghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, et al.Journal of Translational Medicine|December 23, 2011
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinomaXiaoen Wang, Liang Zhang, S Nahum Goldberg, et al.Cancers|September 23, 2022
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109Dongyu Zhang, Neil J Shah, Michael Cook, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.Journal of Cancer|October 6, 2025
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced MelanomaRyan J Sullivan, Katy K Tsai, Anna C Pavlick, et al.Pageof 59